Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab. - Wikidata - awgldk - TriplyDB

Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.

Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.

http://www.wikidata.org/entity/Q37172361

about

Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives Trastuzumab cardiotoxiciy: the age-old balance of risk and benefit.Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast Cancer.

P2860

Q28077666-B0AA3C22-800C-4CB7-A71F-E097C893506D Q47169897-CE130665-2541-4483-8C98-4B281E91BF6A Q49961375-F0F6E88D-799E-42BE-8474-D4E297A961E7

P2860

Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.

http://www.wikidata.org/entity/Q37172361

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical Utility of Routine Ca ...... atients Receiving Trastuzumab.

@en

Clinical Utility of Routine Ca ...... atients Receiving Trastuzumab.

@nl

type

label

Clinical Utility of Routine Ca ...... atients Receiving Trastuzumab.

@en

Clinical Utility of Routine Ca ...... atients Receiving Trastuzumab.

@nl

prefLabel

Clinical Utility of Routine Ca ...... atients Receiving Trastuzumab.

@en

Clinical Utility of Routine Ca ...... atients Receiving Trastuzumab.

@nl

P1433

Q37172361-17AD2255-866E-4DB0-87A9-DC1B509A8A90

P1476

Q37172361-75694007-6E90-4692-8B74-6C1F0572CEA5

P2093

Q37172361-29039131-5672-472A-8799-3BF96DEDA68C

Q37172361-32E77F7D-FAC5-4729-9340-F0981A71E2DE

Q37172361-604153BB-9295-4AAC-A796-F5F7E299AFC1

Q37172361-6D5FD8A2-F2EA-4367-9436-0A50C5284A96

Q37172361-6F9EDEE4-E489-4152-A3E0-54F1A4833E9D

Q37172361-D4ED2A06-4086-4D40-970E-FBDD28E49C85

P2860

Q37172361-018BF83C-A1B5-436B-B9BD-B1A24FEBF488

Q37172361-04809593-76D4-4732-9486-A2A7B84E164B

Q37172361-0F7815E7-4D0D-44C3-B406-C1017AE0C845

Q37172361-31BF8164-B1C9-4192-9FCB-1A6D7354E5EA

Q37172361-364F9091-016F-4366-ACB3-77DBCE8C8522

Q37172361-389BDC45-6733-4A2D-B8AA-9D4031621B4C

Q37172361-397AE010-63B9-4BE4-A906-5EFC021AD986

Q37172361-3CECA272-15E9-43AC-B815-9A8C00D93472

Q37172361-4D49A01D-ECC4-4DFF-A0D1-8A61E1D29776

Q37172361-5C0CA8C1-E11D-4060-9AA8-77A261CA70DC

P304

Q37172361-BF724416-D580-4E85-944D-805220CDB522

P31

Q37172361-D2CEC2FB-4E24-41B1-92B3-084E1B10F9A6

P356

Q37172361-75FE63B6-3F45-4591-9DDC-2BE6812929BC

P407

Q37172361-EEAA17DE-6555-4FD9-AEDF-037A68E7668D

P433

Q37172361-9CB44317-5EBC-48FA-BBC2-14103F5CD239

P478

Q37172361-0E956675-EE5C-4B02-ABAE-76D6D221C363

P577

Q37172361-5611EB85-14FB-401B-A8C4-B5AF05108798

P698

Q37172361-666EA13D-B322-450A-9A83-5A099D53E9E5

P932

Q37172361-7CADB145-AE0C-4974-8923-36FC0F192FFC

P356

1060028016654160

P1433

Annals of Pharmacotherapy

P1476

Clinical Utility of Routine Ca ...... atients Receiving Trastuzumab.

@en

P2093

Amelia Zelnak

http://www.w3.org/2001/XMLSchema#string

Christine C Davis

http://www.w3.org/2001/XMLSchema#string

Daniel A Goldstein

http://www.w3.org/2001/XMLSchema#string

J William Eley

http://www.w3.org/2001/XMLSchema#string

Jeffrey M Switchenko

http://www.w3.org/2001/XMLSchema#string

Trevor McKibbin

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab-containing regimens for metastatic breast cancer

Cancer statistics, 2015

Cardiac dysfunction in the trastuzumab clinical trials experience

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study.

Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis.

Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.

Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

P304

712-717

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1060028016654160

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27307412

http://www.w3.org/2001/XMLSchema#string

P932

4983504

http://www.w3.org/2001/XMLSchema#string